Paradoxical skin lesions induced by anti-TNF-α agents in SAPHO syndrome
The objectives of the study were to characterize the clinical picture of paradoxical skin lesions in SAPHO patients treated with anti-TNF-α agents and to explore its pathogenesis. Patients treated with anti-TNF-α therapy were identified from a cohort of 164 SAPHO patients. The clinical data and skin biopsies were collected. The usage, efficacy, and side effects of anti-TNF-α therapy were recorded. Forty-one (25.0%) patients received anti-TNF-α therapy, of which seven (17.1%) developed paradoxical skin lesions after 1 to 14 infusions. Patients with such lesions were older at onset of skin lesions than those without (p = 0.034). Expression of TNF-α in palmoplantar pustulosis increased after anti-TNF-α therapy in the two examined patients with exacerbated skin lesions. Anti-TNF-α therapy induces paradoxical skin lesions in 17.1% SAPHO patients. Late onset of skin manifestations is associated with an increased risk of such lesions. The paradoxical elevation of TNF-α expression in lesions may contribute to this phenomenon.
KeywordsAge of onset Palmoplantar pustulosis Psoriasiform lesions SAPHO syndrome Side effects Tumor necrosis factor-α inhibitor
This study was supported by China National Natural Science Funds (No. 81371731) and the Capital Medical Research and Development Fund (No. 2016-4-40112), the Education Reform Projects of Peking Union Medical College (No. 2016zlgc0106), the CAMS Initiative for Innovative Medicine (No. 2017-I2M-3-001), and the National Key Research and Development Program of China (No. 2016YFC0901500).
Compliance with ethical standards
The study was approved by the Ethics Committee of Peking Union Medical College Hospital, Peking Union Medical College, and Chinese Academy of Medical Sciences (ethics documents number ZS-944). All individual participants provided written informed consent to participate in this cohort at the time of inclusion.
- 7.Blandizzi C, Gionchetti P, Armuzzi A, Caporali R, Chimenti S, Cimaz R, Cimino L, Lapadula G, Lionetti P, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Girolomoni G (2014) The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 27(1 Suppl):1–10. https://doi.org/10.1177/03946320140270S101 CrossRefPubMedGoogle Scholar
- 9.Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M (2007) Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 156(3):486–491. https://doi.org/10.1111/j.1365-2133.2007.07682.x CrossRefPubMedGoogle Scholar
- 10.Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL (2005) Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 7(3):R666–R676. https://doi.org/10.1186/ar1724 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Li C, Zuo Y, Wu N, Li L, Li F, Zhang W, Xu W, Zhao X, Jing H, Pan Q, Zhou W, Shi X, Fan Y, Wang J, Liu S, Liu Z, Zhang F, Zeng X, Chen H, Zhang S, Liu J, Qiu G, Wu Z, Dong Z, Zhang W (2016) Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a single centre study of a cohort of 164 patients. Rheumatology (Oxford) 55(6):1023–1030. https://doi.org/10.1093/rheumatology/kew015 CrossRefGoogle Scholar
- 17.Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Wetzke M, Maier H, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Brand S (2014) Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 63(4):567–577CrossRefPubMedGoogle Scholar
- 19.Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, Linos E, Liao W, Haemel A (2017) Tumor necrosis factor-alpha inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol 76(2):334–341. https://doi.org/10.1016/j.jaad.2016.08.012 CrossRefPubMedGoogle Scholar
- 20.Laga AC, Vleugels RA, Qureshi AA, Velazquez EF (2010) Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol 32(6):568–573. https://doi.org/10.1097/DAD.0b013e3181cb3ff7 CrossRefPubMedGoogle Scholar
- 21.Guerra I, Pérez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, Chaparro M, Mañosa M, Hinojosa E, Minguez M, Ortiz de Zarate J, Márquez L, Prieto V, García-Sánchez V, Guardiola J, Rodriguez GE, Martín-Arranz MD, García-Tercero I, Sicilia B, Masedo Á, Lorente R, Rivero M, Fernández-Salazar L, Gutiérrez A, van Domselaar M, López-SanRomán A, Ber Y, García-Sepulcre M, Ramos L, Bermejo F, Gisbert JP, Spanish GETECCU group (ENEIDA project) (2016) Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 22(4):894–901CrossRefPubMedGoogle Scholar
- 22.Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taieb A (2009) Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 161(5):1081–1088. https://doi.org/10.1111/j.1365-2133.2009.09329.x CrossRefPubMedGoogle Scholar
- 23.Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg IE (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67(12):1670–1677. https://doi.org/10.1136/ard.2007.077974 CrossRefPubMedGoogle Scholar
- 25.Johnston A, Fritz Y, Dawes SM, Diaconu D, al-Attar PM, Guzman AM, Chen CS, Fu W, Gudjonsson JE, McCormick TS, Ward NL (2013) Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol 190(5):2252–2262. https://doi.org/10.4049/jimmunol.1201505 CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Queiro R, Alonso S, Alperi M, Fernandez M, Sarasqueta C (2011) Stratification by age of onset with 30 years as age limit is an effective means of identifying PSORS1-associated psoriasis in patients with psoriatic arthritis. Joint Bone Spine 78(6):581–583. https://doi.org/10.1016/j.jbspin.2011.02.009 CrossRefPubMedGoogle Scholar